A Review on the Role of Moxifloxacin in the Treatment and Management of Respiratory Tract Infections

Respiratory tract infections (RTIs) constitute a major global health burden, with significant impact on morbidity and mortality rates, particularly among vulnerable populations. Moxifloxacin, a fourth-generation fluoroquinolone, is an important antibiotic for treating various RTIs, including community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), and acute bacterial sinusitis. The drug exhibits potent activity against key respiratory pathogens, including drug-resistant Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms. Its dual mechanism of action targeting bacterial DNA gyrase and topoisomerase IV, combined with favorable pharmacokinetic properties such as high bioavailability and extensive tissue penetration, contributes to its clinical effectiveness. Once-a-daily dose and the ability to switch between oral and intravenous formulations enhance its therapeutic utility. Clinical studies demonstrate comparable or superior efficacy to standard treatments across various RTIs. However, safety considerations include QT interval prolongation, tendinopathy risk, and rare cases of hepatotoxicity, necessitating careful patient selection and monitoring. The emergence of bacterial resistance mechanisms, including mutations in quinolone resistance-determining regions and efflux pumps, requires judicious use to maintain long-term effectiveness. Current evidence indicates that moxifloxacin is a valuable antimicrobial agent for RTIs, particularly in cases involving resistant pathogens or when first-line therapies are contraindicated